NASDAQ$IRON

Disc Medicine Inc · Q3 2025 earnings

Q3 2025 earnings · · Before market open · Investor relations

Briefing

Disc Medicine reported Q3 2025, net loss of $85M.

For Q3 2025, Disc Medicine reported a net loss of $85M. The filing discusses segment trends, liquidity, and management outlook for upcoming periods.

  • Net loss $85M.
  • Disc Medicine highlights operating priorities and capital allocation.
  • Disc Medicine highlights operating priorities and capital allocation.

Headline financials

Total Revenue

$0.00

Previous: $0.00
EPS (adj)

-$1.77

Previous: -$0.89-98.9%
Weighted-average common shares outstanding

35.2M

Previous: 29.9M+17.5%
Net Income

-$85M

Previous: -$26.6M-219.5%
Operating Income

-$67.7M

Previous: -$32.9M-106.0%

Revenue & EPS history

Disc Medicine · Revenue · Quarterly

$0

Q3 2025

Forward guidance

The release discusses Disc Medicine's outlook, capital allocation, and key risks for upcoming quarters, including guidance ranges or operating priorities where disclosed.

Tailwinds

  • Disc Medicine cites demand and execution supporting the near-term outlook.
  • Liquidity and balance-sheet capacity support operations and shareholder returns.

Headwinds

  • GAAP profitability remained under pressure in Q3 2025.
  • Macro, input costs, and FX may pressure margins quarter to quarter.
  • Segment mix and one-time items can affect comparability versus prior periods.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q3 2025

Historical avgQ3 2025

-0.4%

Avg return

Earnings day

-1.7%

Avg return

5 days after

+3.9%

Avg return

30 days after

56%

10 / 18 earnings

Positive

+14.6%

Q3 2021

Best reaction

-12.4%

Q2 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026+1.3%-3.8%-10.2%
Q3 2025-1.6%-2.5%+5.6%
Q2 2025-3.4%+0.1%+3.0%
Q1 2025+2.3%+3.8%+14.1%
Q4 2024+0.1%+1.6%-3.9%
Q3 2024-5.3%-10.7%-3.5%
Q1 2024+3.5%+8.5%+33.3%
Q4 2023-8.7%-9.2%-56.8%
Q3 2023+1.7%+8.1%+27.8%
Q2 2023+0.3%+1.9%-1.2%
Q1 2023+0.6%+1.8%+47.6%
Q4 2022-0.6%+0.7%+48.4%
Q3 2022-0.6%-4.7%-2.4%
Q2 2022-12.4%-10.9%-31.8%
Q1 2022+3.6%+10.1%+8.6%
Q4 2021-3.2%-7.7%-11.0%
Q3 2021+14.6%-5.6%-12.6%
Q2 2021+0.2%-12.8%+15.3%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro